<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Social Medicine</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0C649249-D4B7-4443-91A2-A61B5C1FC3CF"><gtr:id>0C649249-D4B7-4443-91A2-A61B5C1FC3CF</gtr:id><gtr:firstName>Kate</gtr:firstName><gtr:surname>Birnie</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK021699%2F1"><gtr:id>C3EC2B03-8290-4CE5-A7D7-5C5B8608E09B</gtr:id><gtr:title>Erythropoietin therapy for treating anaemia among haemodialysis patients: associations with survival and comparison of treatment strategies</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/K021699/1</gtr:grantReference><gtr:abstractText>People with kidney disease are often anaemic, which can reduce their quality of life, with symptoms of fatigue, dizziness, and shortness of breath. Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below normal. The kidneys produce a substance called erythropoietin (EPO) which stimulates the bone marrow to produce red blood cells. Loss of EPO production is a major cause of anaemia in renal failure. Anaemia is measured by blood haemoglobin levels, and can be treated by injections of EPO in drug form. However, at present we do not know enough about the safety of high doses of EPO. 

This study aims to establish the best use of EPO treatment for patients with chronic kidney disease on haemodialysis, a treatment that takes over the work of the kidneys if they fail. The UK Renal Registry collects data on adults receiving renal replacement therapy from all centres across the UK, and will provide data on patients receiving haemodialysis. Relevant patient information will be extracted from the database, including data on age, sex, disease information, results from blood tests, EPO dose and treatment dates.

I will look at haemoglobin levels in patients and EPO dosing over time in the UK, and will compare trends to changes in the UK treatment guidelines. I will see by how much haemoglobin levels differ between people and will examine patterns of repeated haemoglobin levels within individual patients. I will investigate how many people become resistant to EPO therapy. EPO resistance describes patients who fail to reach a haemoglobin target despite a higher than usual dose of EPO, or patients who continuously need a higher dose in order to keep their haemoglobin at a particular level. I will see which factors predict whether people get treated with EPO and examine if EPO treatment is related to the survival of patients. Finally, I will use novel statistical techniques to investigate which strategy for correcting anaemia gives the best survival and the lowest risk of hospitalisation. Findings will be important as they will help clinicians be more aware of the appropriate EPO dosage for haemodialysis patients.</gtr:abstractText><gtr:technicalSummary>Background: Anaemia is common in people with kidney disease and results in reduced quality of life, including symptoms of fatigue, dizziness, and shortness of breath. Anaemia can be treated by injections of erythropoietin (EPO). However, at present we do not know enough about the safety of high doses of EPO or of full correction of anaemia to normal haemoglobin levels. 

Aims and objectives: We aim to establish the optimal use of EPO therapy for haemodialysis patients. I will describe haemoglobin levels in patients and EPO dosing over time in the UK, and will compare trends to changes in the national Renal Associations guidelines for management of anaemia. I will describe haemoglobin variability and EPO resistance in individuals. I will quantify the predictors of EPO treatment and examine the effect of EPO dose on mortality. Finally I will compare different treatment strategies to optimise survival and give the lowest risk of hospitalisation.

Methods: The UK Renal Registry regularly collects data on adults receiving renal replacement therapy from all centres across the UK, and will provide data on patients receiving haemodialysis. Relevant patient information will be extracted from the database, including: age, sex, disease information, results from blood tests, EPO dose and treatment dates. I will apply marginal structural models to correctly control for time-dependent confounding, and the novel statistical methods of dynamic marginal structural models to compare different treatment strategies for optimising survival.

Our findings will provide insights to clinicians on the correct dosing of EPO for haemodialysis patients, and improve the care for patients.</gtr:technicalSummary><gtr:potentialImpactText>The overall aim of the project is to improve clinical decision-making and, ultimately, to improve care for patients. Potential beneficiaries of the proposed research project are therefore patients with chronic kidney disease on haemodialysis, and health professionals caring for such patients. This study will give insights into EPO resistance and will help clinicians be more aware of the appropriate dosage for certain patient groups. 

The optimal treatment strategy for the dealing with renal anaemia remains controversial and there is a risk that the current treatment guidelines may prevent patients without major co-morbidity from receiving the maximum benefit from treatment. Via one of my collaborators, Dr Charlie Tomson (Renal Association Past-President), I will send my findings to the authors of the Renal Association guidelines, in order to impact on clinical practice.

The NHS will benefit, as knowledge about the correct treatment of anaemia will prevent the need for expensive hospitalisation, thereby creating savings.

Full details of dissemination and engagement activities are in the 'impact to pathways' statement.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>279690</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8A2906B6-87B6-4F87-A741-AB186EAC39AF</gtr:id><gtr:title>An evaluation of a multi-component adult weight management on referral intervention in a community setting.</gtr:title><gtr:parentPublicationTitle>BMC research notes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd195b07261a2fde9c506f5f991b7d7a"><gtr:id>fd195b07261a2fde9c506f5f991b7d7a</gtr:id><gtr:otherNames>Birnie K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-0500</gtr:issn><gtr:outcomeId>56d993ad09d3d2.69991822</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BB5F95B-5BCA-4D34-8940-719CBF0B1BCB</gtr:id><gtr:title>Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd195b07261a2fde9c506f5f991b7d7a"><gtr:id>fd195b07261a2fde9c506f5f991b7d7a</gtr:id><gtr:otherNames>Birnie K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>58ac2e000fd9a5.45714945</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>833D6865-E1B0-4DC9-B3BB-7717C298121A</gtr:id><gtr:title>Predictive models for kidney disease: improving global outcomes (KDIGO) defined acute kidney injury in UK cardiac surgery.</gtr:title><gtr:parentPublicationTitle>Critical care (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd195b07261a2fde9c506f5f991b7d7a"><gtr:id>fd195b07261a2fde9c506f5f991b7d7a</gtr:id><gtr:otherNames>Birnie K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1364-8535</gtr:issn><gtr:outcomeId>5675dfac45e0e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>209F0086-4843-48C7-9DE3-3543C7A6ACE9</gtr:id><gtr:title>Accuracy of cystatin C for the detection of abnormal renal function in children undergoing chemotherapy for malignancy: a systematic review using individual patient data.</gtr:title><gtr:parentPublicationTitle>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce860bc84e4e847664fa56855a55b5"><gtr:id>f1ce860bc84e4e847664fa56855a55b5</gtr:id><gtr:otherNames>Whiting P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0941-4355</gtr:issn><gtr:outcomeId>5a82f703bfcda0.20215743</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F9AD283-884A-456B-99C2-2FB501D32A6B</gtr:id><gtr:title>Comparison of microbiological diagnosis of urinary tract infection in young children by routine health service laboratories and a research laboratory: Diagnostic cohort study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd195b07261a2fde9c506f5f991b7d7a"><gtr:id>fd195b07261a2fde9c506f5f991b7d7a</gtr:id><gtr:otherNames>Birnie K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58ac28d54ac9b3.34858163</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K021699/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>